Clinical study on the treatment of chronic urticaria with different doses of ebastine combined with compound glycyrrhizin decremental therapy
Objective:To study the clinical effects of different doses of ebastine combined with compound glycyrrhizin decremental therapy in the treatment of chronic urticaria.Methods:A total of 44 patients with chronic urticaria treated in our hospital from January 2022 to September 2023 were selected as the study subjects.They were divided into the control group and the observation group according to different treatment plans,with 22 cases in each group.The control group was treated with 10 mg of ebastine tablets,and the observation group was treated with 20 mg of ebastine.Both groups were given compound glycyrrhizin decremental therapy.Clinical symptom scores,hematological indicators[interleukin-17(IL-17),interleukin-25(IL-25)and interleukin-33(IL-33)],T lymphocyte count[helper T cell(CD4+)and cytotoxic T cell(CD8+)],clinical effects,and the incidence of adverse drug reactions were compared between the two groups.Results:After treatment,clinical symptom scores of the observation group were lower than those of the control group(P<0.05),and total effective rate was higher than that of the control group(P<0.05).After treatment,the levels of IL-17,IL-25,IL-33 and CD8+in the observation group were lower than those in the control group,and the level of CD4+was higher than that in the control group(P<0.05).The incidence rates of adverse reactions in the two groups were similar.Conclusion:20 mg of ebastine combined with compound glycyrrhizin decremental therapy can alleviate clinical symptoms in patients with chronic urticaria more effectively,reduce serum IL-17,IL-25 and IL-33 levels,and improve immune function,with quite high safety.
EbastineDifferent dosesCompound glycyrrhizinDecremental therapyChronic urticariaClinical study
NETL
NSTL
万方数据
